ReviewJournal of pharmacy & bioallied sciences2025
Drug-Induced Liver Injury: Mechanisms, Diagnosis, and Management: A Review.
Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Casticin Alleviates Acetaminophen-Induced Acute Liver Injury by Modulating the TLR4/MyD88/TRAF6/NF-κB Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury.Cureus · 2026Review
- Diagnostic value of drug withdrawal observation in drug-induced liver injury: A retrospective study.Medicine · 2026Article
- Unraveling the Antihyperglycemic Effects of Dipeptyl Peptidase-4 Inhibitors in Rodents: A Multi-Faceted Approach Combining Effects on Glucose Homeostasis, Molecular Docking, and ADMET Profiling.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Fermentation of Panax ginseng C.A. Meyer extract with lactic acid bacteria exerts hepatoprotective effects via activating the NRF2 pathway.Journal of molecular histology · 2025Article
- Machine learning-assisted analysis of serum metabolomics for identifying biomarkers in intrinsic and idiosyncratic drug-induced liver injury.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) stands as the worldwide medical problem that causes substantial portions of both acute liver failure incidents and necessary liver transplants and fatalities. The liver functions as the main detoxifying organ of the body therefore, it becomes easily susceptible to destructive effects from the medicine components as well as other substances such as herbal supplements. DILI produces diverse liver damage that extends from unnoticed enzyme level elevations through the acute liver failure detection points. The purpose of this review assessment is to deliver an extensive breakdown of DILI pathogenic elements alongside diagnostic hurdles and present rule-of-the-art clinical practices. Researchers analyze three major pathophysiological mechanisms-oxidative stress, along with mitochondrial dysfunction and immune-mediated damage-for liver damage formation. The article explains diagnostic tools for DILI alongside establishing biomarkers and employment of liver biopsy for diagnosis. This discussion explores detailed information about the three management options that consist of drug withdrawal and supportive care together with liver transplantation. The discovery of genetic DILI susceptibilities combined with pharmacogenomic applications in clinical care leads to promising patient-specific treatments for better clinical achievements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.